menu
    • menu
    [{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QED Therapeutics \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"LianBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"QED Therapeutics \/ QED Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"QED Therapeutics \/ QED Therapeutics"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"QED Therapeutics \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"QED Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"QED Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"QED Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"QED Therapeutics \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"QED Therapeutics \/ QED Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ QED Therapeutics"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"QED Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"QED Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"QED Therapeutics","amount2":2,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"Capsule","sponsorNew":"QED Therapeutics \/ QED Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ QED Therapeutics"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QED Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"QED Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"QED Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Jennifer Lee Caswell-Jin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QED Therapeutics \/ Jennifer Lee Caswell-Jin","highestDevelopmentStatusID":"6","companyTruncated":"QED Therapeutics \/ Jennifer Lee Caswell-Jin"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Guru P. Sonpavde","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QED Therapeutics \/ Guru P. Sonpavde","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ Guru P. Sonpavde"}]

    Find Clinical Drug Pipeline Developments & Deals by QED Therapeutics

    Menu

    QED Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

                            Details : Infigratinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Achondroplasia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 11, 2025

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Interventional Study of Infigratinib in Children With Hypochondroplasia

                            Details : Infigratinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hypochondroplasia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2025

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

                            Details : Infigratinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Achondroplasia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 11, 2023

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : LianBio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients wit...

                            Details : Truseltiq (infigratinib) is an oral small molecule, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven gastric cancer or gastroesophageal junction adenocarcinoma and to target achondroplasia at its source.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 06, 2023

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : LianBio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Extension Study of Infigratinib in Children With Achondroplasia (ACH)

                            Details : Infigratinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Achondroplasia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 06, 2021

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Guru P. Sonpavde

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I BLASST-3 Trial

                            Details : Infigratinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Transitional Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 22, 2021

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Guru P. Sonpavde

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : BridgeBio Pharma

                            Deal Size : $2,000.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bridgebio Pharma’s Affiliate Qed Therapeutics and Helsinn Group Announce Strategic Collaboration for Infigra...

                            Details : BridgeBio will retain all rights to infigratinib in skeletal dysplasia, including achondroplasia. Subject to U.S. FDA approval, QED and Helsinn will co-commercialize infigratinib in oncology indications in the U.S. and will share profits and losses on a ...

                            Product Name : Truseltiq

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 31, 2021

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : BridgeBio Pharma

                            Deal Size : $2,000.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : BridgeBio Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Accepts Of New Drug Application For BridgeBio Pharma And QED's Infigratinib For The Treatment Of Cholangio...

                            Details : The U.S. FDA has accepted New Drug Application (NDA) for infigratinib, an oral FGFR1-3 selective inhibitor, for individuals with cholangiocarcinoma, or cancer of the bile ducts. Application accepted under Priority Review designation.

                            Product Name : Truseltiq

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 01, 2020

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : BridgeBio Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Jennifer Lee Caswell-Jin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered ...

                            Details : Infigratinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 07, 2020

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Jennifer Lee Caswell-Jin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            QED Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carci...

                            Details : Data will be presented reports consistent treatment response in both first-line and later-line treatment settings after Infigratinib (BGJ398) treatment in advanced/unresectable or metastatic urothelial carcinoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 29, 2020

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth